135 related articles for article (PubMed ID: 32728822)
1. Cost-Effectiveness of Utilization of Hepatitis B Virus-Positive Liver Donors for HBV-Negative Transplant Recipients.
Lee TC; Eckman MH; Shah SA
J Gastrointest Surg; 2021 Jul; 25(7):1760-1769. PubMed ID: 32728822
[TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
[TBL] [Abstract][Full Text] [Related]
7. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.
Bethea ED; Samur S; Kanwal F; Ayer T; Hur C; Roberts MS; Terrault N; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):739-747.e8. PubMed ID: 30138735
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
12. Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021.
Ali SE; Vutien P; Bonham CA; Landis C; Kwo P; Esquivel C; Nguyen MH
Liver Transpl; 2023 Jan; 29(1):80-90. PubMed ID: 35844046
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
14. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective.
Saab S; Kardashian A; Saggi S; Choi G; Agopian V; Tong MJ
Clin Transplant; 2018 Oct; 32(10):e13383. PubMed ID: 30129981
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.
Kadatz M; Klarenbach S; Gill J; Gill JS
Am J Transplant; 2018 Oct; 18(10):2457-2464. PubMed ID: 29797402
[TBL] [Abstract][Full Text] [Related]
16. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
Xie L; Yin J; Xia R; Zhuang G
Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304
[TBL] [Abstract][Full Text] [Related]
18. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China.
Lei M; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG
World J Gastroenterol; 2018 Dec; 24(48):5525-5536. PubMed ID: 30622380
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
